309 related articles for article (PubMed ID: 25213349)
21. Non-linear dynamic analysis of clozapine-induced electroencephalographic changes in schizophrenic patients--a preliminary study.
Kang UG; Par KT; Ahn YM; Koo YJ; Yoon SC; Yi SH; Kim YS
Prog Neuropsychopharmacol Biol Psychiatry; 2001 Aug; 25(6):1229-39. PubMed ID: 11474842
[TBL] [Abstract][Full Text] [Related]
22. Clozapine and desmethylclozapine: correlation with neutrophils and leucocytes counting in Mexican patients with schizophrenia.
Vaquero-Baez M; Díaz-Ruíz A; Tristán-López L; Aviña-Cervantes C; Torner C; Ramírez-Bermúdez J; Montes S; Ríos C
BMC Psychiatry; 2019 Oct; 19(1):295. PubMed ID: 31597566
[TBL] [Abstract][Full Text] [Related]
23. Determination of pharmacokinetic properties of clozapine and norclozapine in Korean schizophrenia patients.
Lee ST; Ryu S; Nam HJ; Lee SY; Hong KS
Int Clin Psychopharmacol; 2009 May; 24(3):139-44. PubMed ID: 19194306
[TBL] [Abstract][Full Text] [Related]
24. Clozapine, but not typical antipsychotics, correct P50 suppression deficit in patients with schizophrenia.
Becker J; Gomes I; Ghisolfi ES; Schuch A; Ramos FL; Ehlers JA; Nora DB; Lara DR; da Costa JC
Clin Neurophysiol; 2004 Feb; 115(2):396-401. PubMed ID: 14744582
[TBL] [Abstract][Full Text] [Related]
25. A machine learning approach for distinguishing age of infants using auditory evoked potentials.
Ravan M; Reilly JP; Trainor LJ; Khodayari-Rostamabad A
Clin Neurophysiol; 2011 Nov; 122(11):2139-50. PubMed ID: 21571586
[TBL] [Abstract][Full Text] [Related]
26. Effects of clozapine on auditory event-related potentials in schizophrenia.
Umbricht D; Javitt D; Novak G; Bates J; Pollack S; Lieberman J; Kane J
Biol Psychiatry; 1998 Oct; 44(8):716-25. PubMed ID: 9798075
[TBL] [Abstract][Full Text] [Related]
27. Investigating Predictors of Clozapine Response in Adolescents with Schizophrenia and Schizoaffective Disorder.
Karacetin G; Ermis C; Bulanik Koc E; Saglam Y
J Child Adolesc Psychopharmacol; 2021 Sep; 31(7):504-510. PubMed ID: 34283936
[No Abstract] [Full Text] [Related]
28. Clozapine and global cognition in schizophrenia.
Rajji TK; Uchida H; Ismail Z; Ng W; Mamo DC; Remington G; Pollock BG; Mulsant BH
J Clin Psychopharmacol; 2010 Aug; 30(4):431-6. PubMed ID: 20631560
[TBL] [Abstract][Full Text] [Related]
29. Discriminative stimulus properties of the atypical antipsychotic clozapine and the typical antipsychotic chlorpromazine in a three-choice drug discrimination procedure in rats.
Porter JH; Prus AJ; Vann RE; Varvel SA
Psychopharmacology (Berl); 2005 Feb; 178(1):67-77. PubMed ID: 15316715
[TBL] [Abstract][Full Text] [Related]
30. Differences between physicians' and nurse practitioners' viewpoints on reasons for clozapine underprescription.
Okhuijsen-Pfeifer C; Cohen D; Bogers JPAM; de Vos CMH; Huijsman EAH; Kahn RS; Luykx JJ
Brain Behav; 2019 Jul; 9(7):e01318. PubMed ID: 31144470
[TBL] [Abstract][Full Text] [Related]
31. LORETA functional imaging in antipsychotic-naive and olanzapine-, clozapine- and risperidone-treated patients with schizophrenia.
Tislerova B; Brunovsky M; Horacek J; Novak T; Kopecek M; Mohr P; Krajca V
Neuropsychobiology; 2008; 58(1):1-10. PubMed ID: 18781085
[TBL] [Abstract][Full Text] [Related]
32. Safety evaluation of the concomitant use of clozapine and benzodiazepines: a retrospective, cross-sectional chart review.
Bitter R; Demler TL; Opler L
J Psychiatr Pract; 2008 Sep; 14(5):265-70. PubMed ID: 18832957
[TBL] [Abstract][Full Text] [Related]
33. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients.
Carrillo JA; Herraiz AG; Ramos SI; Benítez J
J Clin Psychopharmacol; 1998 Aug; 18(4):311-6. PubMed ID: 9690697
[TBL] [Abstract][Full Text] [Related]
34. EEG abnormalities before clozapine therapy predict a good clinical response to clozapine.
Pillay SS; Stoll AL; Weiss MK; Tohen M; Zarate CA; Banov MD; Cole JO
Ann Clin Psychiatry; 1996 Mar; 8(1):1-5. PubMed ID: 8743641
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia.
Nakata Y; Kanahara N; Kimura H; Watanabe H; Iyo M
Int Clin Psychopharmacol; 2017 May; 32(3):169-173. PubMed ID: 28067751
[TBL] [Abstract][Full Text] [Related]
36. Augmentation of clozapine with another pharmacological agent: treatment for refractory schizophrenia in the 'real world'.
Pai NB; Laidlaw M; Vella SC
Acta Psychiatr Scand; 2012 Jul; 126(1):40-6. PubMed ID: 22432694
[TBL] [Abstract][Full Text] [Related]
37. Colonic transit diagnostic test shows significant gastrointestinal hypomotility in clozapine-treated patients in comparison with subjects treated with other antipsychotics.
Baptista T; Carrizo E; Fernandez E; Connell L; Servigna M; Parra A; Quintero J; Pabón A; Sandia I; Uzcáteguid E; Serrano A; Pirela N; Villarreal L
Schizophr Res; 2015 Aug; 166(1-3):207-11. PubMed ID: 26032569
[TBL] [Abstract][Full Text] [Related]
38. Long-term replicability of EEG spectra and auditory evoked potentials in schizophrenic and normal subjects.
Lifshitz K; Lee KL; Susswein S
Neuropsychobiology; 1987; 18(4):205-11. PubMed ID: 2900484
[TBL] [Abstract][Full Text] [Related]
39. Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine.
Muscatello MR; Bruno A; De Fazio P; Segura-Garcia C; Pandolfo G; Zoccali R
Expert Opin Pharmacother; 2014 Nov; 15(16):2329-45. PubMed ID: 25284216
[TBL] [Abstract][Full Text] [Related]
40. Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: A systematic review and meta-analysis.
Okhuijsen-Pfeifer C; Sterk AY; Horn IM; Terstappen J; Kahn RS; Luykx JJ
Neurosci Biobehav Rev; 2020 Apr; 111():246-252. PubMed ID: 31982601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
